Xenon Pharmaceuticals Inc (XENE)
Healthcare
Biotechnology
62.70 $
-2.4%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Xenon Pharmaceuticals Inc (XENE)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 93.9% of the shares are freely tradable; institutional investors hold 107.4%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
107.4%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
93.9%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
4.6%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
97Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 11.19 | 10,818,491 | +21.3 | 03/31/2026 |
| venBio Select Advisor LLC | 5.98 | 5,777,777 | +6.5 | 03/31/2026 |
| BlackRock Inc | 5.83 | 5,640,118 | +10.6 | 03/31/2026 |
| Wellington Management Company LLP | 5.00 | 4,829,641 | +1.4 | 03/31/2026 |
| Driehaus Capital Management LLC | 4.65 | 4,491,653 | -1.0 | 03/31/2026 |
| Polar Capital Holdings PLC | 4.56 | 4,405,312 | +78.7 | 03/31/2026 |
| HHG PLC | 4.32 | 4,175,982 | +2.3 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 3.62 | 3,501,794 | -13.6 | 03/31/2026 |
| Vanguard Health Care Inv | 3.33 | 3,214,968 | -3.8 | 03/31/2026 |
| Strategic Advisers Fidelity US TtlStk | 3.17 | 3,064,225 | +2.3 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.